As physicians turn to mammography as a more reliable way to diagnose breast cancer, a new study shows that the screening method does not reduce the number of deaths from the disease and could lead to overdiagnosis, suggesting a few kinks in the system.
Esperion, at work on a cholesterol-lowering pill it hopes can disrupt some high-profile new injections, convinced the FDA to remove a partial clinical hold on the highest dose of its drug.
Working off of an $80 million crossover round with newly won boasting rights to the FDA's breakthrough therapy designation in hand, Brisbane, CA-based Aimmune Therapeutics is wasting no time in diving into the heated IPO waters for biotech. The biotech filed plans to raise $115 million on Nasdaq, the latest in a scrum of developers anxious to tap into the long-running boom market.
Merck is bowing out of the hectic late-stage scramble to be the first to market with a CGRP migraine drug, handing over its portfolio and two experimental drugs in the pipeline to Allergan for $250 million in cash.
The Defense Advanced Research Projects Agency has re-upped in its long-standing relationship with DEKA Innovative Solutions. This time, it's putting $7 million into develop a prosthetic arm with a sense of touch.
Tightly and automatically matching the release of hormones such as insulin to control blood sugar levels for Type 1 diabetics is the Holy Grail in the development of an artificial pancreas. Now researchers may have come one step closer with a fully implantable insulin delivery and glucose sensing system that is guided by a novel algorithm.
Versartis has cleared a roadblock in its path to launching a long-acting treatment for growth hormone deficiency, resolving an FDA clinical hold and getting back on track with its Phase III program.
Allergan will acquire clinical-stage dry eye device startup Oculeve for $125 million plus undisclosed commercial milestone payments tied to lead program, OD-O1. The somewhat stealthy startup came out of the Stanford Biodesign program and counts Kleiner Perkins Caufield & Byers, New Enterprise Associates and Versant Ventures among its investors.
China's Guangxi Wuzhou Zhongheng Group disclosed that it intends to purchase a 10% stake in Israeli pharma company Oramed for $52 million, in return for exclusive Chinese distribution rights to its oral insulin following regulatory approval, according to a briefing from Reuters.
Novartis has opened a new front in its push into digital health. The latest move sees the Big Pharma bring its navigation app for visually impaired people to Apple and Google's smartwatch platforms.